Clinical Trials
4 trialsNCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT02740712 2023-06-09
DDI
pharmaand GmbH
Phase 1 Completed
NCT02106845 2019-06-07
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Bayer
Phase 1 Completed
NCT01517399 2019-02-12
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
Daiichi Sankyo
Phase 1 Completed